InMed Pharmaceuticals (INM) Return on Capital Employed: 2022-2025
Historic Return on Capital Employed for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -0.62%.
- InMed Pharmaceuticals' Return on Capital Employed rose 13.00% to -0.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.62%, marking a year-over-year increase of 13.00%. This contributed to the annual value of -0.67% for FY2025, which is 8.00% up from last year.
- Per InMed Pharmaceuticals' latest filing, its Return on Capital Employed stood at -0.62% for Q3 2025, which was up 17.12% from -0.75% recorded in Q2 2025.
- In the past 5 years, InMed Pharmaceuticals' Return on Capital Employed ranged from a high of -0.52% in Q1 2024 and a low of -1.72% during Q3 2022.
- Its 3-year average for Return on Capital Employed is -0.78%, with a median of -0.75% in 2024.
- In the last 5 years, InMed Pharmaceuticals' Return on Capital Employed spiked by 105bps in 2023 and then tumbled by 64bps in 2025.
- Over the past 4 years, InMed Pharmaceuticals' Return on Capital Employed (Quarterly) stood at -1.19% in 2022, then skyrocketed by 58bps to -0.61% in 2023, then tumbled by 41bps to -1.02% in 2024, then grew by 13bps to -0.62% in 2025.
- Its Return on Capital Employed was -0.62% in Q3 2025, compared to -0.75% in Q2 2025 and -1.16% in Q1 2025.